Research & KnowledgeEvent: September 4, 2026
Bambusa Therapeutics shared two datasets for the first time regarding the BBT002 lead program targeting IL-4Rα and IL-5.
Published
Signal category
Research & Knowledge
Quote
“We're sharing two datasets for the first time, and we couldn't be more excited about what they show.”
— Bambusa Therapeutics team
Company
Bambusa Therapeutics
Transforming I&I Treatment with Next-Generation Bispecific Antibodies
- Industry
- Biotechnology Research
- Location
- BOSTON, US
- Company size
- 22 employees
Bambusa Therapeutics believes the I&I field is long overdue for innovative approaches and transformative therapeutics. Since our inception, we have built a diverse portfolio of molecules and are uniquely positioned to make significant contributions to patients suffering from debilitating and chronic inflammatory conditions.
Founded 2024